Guru Ownership Trend
Guru Analysis for Galectin Therapeutics Inc. (GALT)
Galectin Therapeutics Inc. (GALT), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $624,802.29.
Top institutional holders include Renaissance Technologies (RenTech) and Murray Stahl.
Institutional sentiment is currently Bullish. This is evidenced by a $394,491.86 net inflow during the quarter.
Recent activity highlights Renaissance Technologies (RenTech) who opened a new position. Conversely, Jefferies Group reduced exposure by 25.8%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Galectin Therapeutics Inc. (GALT)
Major holders include Renaissance Technologies (RenTech) ($412,641), Murray Stahl ($137,341), Jefferies Group ($34,005). According to the latest reported data, 3 tracked investment managers collectively hold approximately 209,314 shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $394,491.86, with 1 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 0 fully exited GALT. The total reported sell value was $18,149.14.
Yes, 1 managers opened new positions in GALT, and 0 increased their existing holdings. The total reported buy value was $412,641.